Ahead of time. The virus mutates, so do we... with the d-genotype.
SUIGEN PCV2 is an inactivated vaccine against de porcine circovirus, it is the first available commercial vaccines (among international players) containing the d-genotype which is today the predominant genotype on the field in most regions of the world.
The first global PCV-2d vaccine formulated with the d-genotype to better fit predominant field challenges.
Complete antigenic offer to stimulate the immune system
Innovative vaccination protocol that will include sow vaccination and diagnostic testing to adjust vaccination date of piglets
And vaccination management to ensure vaccination success
Piglets vaccination allows:
- Significant reduction of PCV-2 prevalence and clinical severity
- Lesser mortality and cull rates
- Improvement of ADWG and feed conversion rate
- Decrease in the frequency of co-infections
- Reduction of viral-induced microscopic PCV-2-SD-like lymphoid lesions and viral load in tissues and blood
A number of infectious agents have been described as potential PCV-2 triggers under experimental and field conditions:
- Porcine parvovirus (PPV)
- Porcine reproductive and respiratory syndrome virus (PRRSV)
- Mycoplasma hyopneumoniae
However, the list of infectious agents found in concomitance with PCV-2 cases under natural conditions is much more extensive.
Vaccination against PCV-2 does not only imply direct beneficial effects on pig productivity, but also contributes to reduction of antimicrobial use
-resize1680x1119-crop1470x384.jpg)
.png)
